These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 29413518)

  • 21. Prevention of suicide by clozapine in mental disorders: systematic review.
    Masdrakis VG; Baldwin DS
    Eur Neuropsychopharmacol; 2023 Apr; 69():4-23. PubMed ID: 36640481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clozapine: current status and role in the pharmacotherapy of schizophrenia.
    Remington GJ; Addington D; Collins EJ; Jones BD; Lalonde P; MacCrimmon DJ; MacEwan GW
    Can J Psychiatry; 1996 Apr; 41(3):161-6. PubMed ID: 8722645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clozapine and resistant schizophrenia].
    Pere JJ; Chaumet-Riffaud D
    Encephale; 1990; 16(2):143-5. PubMed ID: 1972053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of clozapine on aggression and substance abuse in schizophrenic patients.
    Volavka J
    J Clin Psychiatry; 1999; 60 Suppl 12():43-6. PubMed ID: 10372611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey.
    Zimmet SV; Strous RD; Burgess ES; Kohnstamm S; Green AI
    J Clin Psychopharmacol; 2000 Feb; 20(1):94-8. PubMed ID: 10653215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classics in chemical neuroscience: clozapine.
    Wenthur CJ; Lindsley CW
    ACS Chem Neurosci; 2013 Jul; 4(7):1018-25. PubMed ID: 24047509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clozapine: new research on efficacy and mechanism of action.
    Meltzer HY; Bastani B; Ramirez L; Matsubara S
    Eur Arch Psychiatry Neurol Sci; 1989; 238(5-6):332-9. PubMed ID: 2569975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment.
    Meltzer HY; Okayli G
    Am J Psychiatry; 1995 Feb; 152(2):183-90. PubMed ID: 7840350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment-resistant schizophrenia].
    Yahyaten OB
    Rev Med Brux; 2014; 35(3):169-73. PubMed ID: 25102584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is clozapine antisuicidal?
    Kerwin RW; Bolonna AA
    Expert Rev Neurother; 2004 Mar; 4(2):187-90. PubMed ID: 15853559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clozapine: a clinical review of adverse effects and management.
    Iqbal MM; Rahman A; Husain Z; Mahmud SZ; Ryan WG; Feldman JM
    Ann Clin Psychiatry; 2003 Mar; 15(1):33-48. PubMed ID: 12839431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A historical perspective of clozapine.
    Hippius H
    J Clin Psychiatry; 1999; 60 Suppl 12():22-3. PubMed ID: 10372606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences.
    Aringhieri S; Carli M; Kolachalam S; Verdesca V; Cini E; Rossi M; McCormick PJ; Corsini GU; Maggio R; Scarselli M
    Pharmacol Ther; 2018 Dec; 192():20-41. PubMed ID: 29953902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The risk of suicide after clozapine discontinuation: Cause for concern.
    Patchan KM; Richardson C; Vyas G; Kelly DL
    Ann Clin Psychiatry; 2015 Nov; 27(4):253-6. PubMed ID: 26554366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.
    Kapur S; McClelland RA; VanderSpek SC; Wadenberg ML; Baker G; Nobrega J; Zipursky RB; Seeman P
    Neuroreport; 2002 May; 13(6):831-5. PubMed ID: 11997696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia.
    de Bartolomeis A; Vellucci L; Barone A; Manchia M; De Luca V; Iasevoli F; Correll CU
    Pharmacol Ther; 2022 Aug; 236():108236. PubMed ID: 35764175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What's atypical about atypical antipsychotic drugs?
    Meltzer HY
    Curr Opin Pharmacol; 2004 Feb; 4(1):53-7. PubMed ID: 15018839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?
    Carpenter WT; Zito JM; Vitrai J; Volavka J
    Biol Psychiatry; 1998 Jan; 43(2):79-83. PubMed ID: 9474440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine.
    Arranz MJ; Collier DA; Munro J; Sham P; Kirov G; Sodhi M; Roberts G; Price J; Kerwin RW
    Neurosci Lett; 1996 Oct; 217(2-3):177-8. PubMed ID: 8916101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain.
    Advokat C
    Essent Psychopharmacol; 2005; 6(2):73-90. PubMed ID: 15765792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.